These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 19484784

  • 1. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA.
    Cancer; 2009 Sep 01; 115(17):3887-96. PubMed ID: 19484784
    [Abstract] [Full Text] [Related]

  • 2. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H, Zang C, Emde A, Planas-Silva MD, Rosche M, Kühnl A, Schulz CO, Elstner E, Possinger K, Eucker J.
    Eur J Pharmacol; 2008 Sep 04; 591(1-3):43-51. PubMed ID: 18588872
    [Abstract] [Full Text] [Related]

  • 3. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S.
    Cancer Chemother Pharmacol; 2008 Jul 04; 62(2):305-13. PubMed ID: 17912526
    [Abstract] [Full Text] [Related]

  • 4. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.
    Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri P, Ribatti D, Ponzoni M.
    Clin Cancer Res; 2007 Jul 01; 13(13):3977-88. PubMed ID: 17606732
    [Abstract] [Full Text] [Related]

  • 5. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 6. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A.
    Cancer Res; 2006 Feb 15; 66(4):2305-13. PubMed ID: 16489035
    [Abstract] [Full Text] [Related]

  • 7. [Effect of chemotherapy with cisplatin and rapamycin against Hep-2 cells in vitro].
    Lei WB, Jia T, Su ZZ, Wen WP, Zhu XL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct 15; 28(10):1838-41. PubMed ID: 18971185
    [Abstract] [Full Text] [Related]

  • 8. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
    Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T.
    Mol Carcinog; 2008 Jun 15; 47(6):446-57. PubMed ID: 18058806
    [Abstract] [Full Text] [Related]

  • 9. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
    Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB.
    Cancer Res; 1995 May 01; 55(9):1982-8. PubMed ID: 7728769
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
    Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, Minegishi T.
    Eur J Cancer; 2006 May 01; 42(7):934-47. PubMed ID: 16540312
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F.
    Endocr Relat Cancer; 2008 Mar 01; 15(1):257-66. PubMed ID: 18310292
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 Mar 01; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 15. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB, Miron P, Miron A, Iglehart JD.
    J Surg Res; 2007 Mar 01; 138(1):37-44. PubMed ID: 17109887
    [Abstract] [Full Text] [Related]

  • 16. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 01; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. p53 dependence and apoptosis in response to FP treatment with p53-transfected colon cancer cell lines by use of thin layer collagen gel.
    Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S.
    Oncol Rep; 2004 Aug 01; 12(2):357-61. PubMed ID: 15254702
    [Abstract] [Full Text] [Related]

  • 19. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
    Engel JB, Honig A, Schönhals T, Weidler C, Häusler S, Krockenberger M, Grunewald TG, Dombrowski Y, Rieger L, Dietl J, Wischhusen J.
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov 01; 141(1):64-9. PubMed ID: 18687514
    [Abstract] [Full Text] [Related]

  • 20. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.